IMTX
ImmaticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful clinical readouts and a partnering deal validate the TCR approach, significantly derisking the pipeline and enabling re-rating toward mid-to-high teens per share; commercialization or buyout optionality could push value higher.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.9.
What can break
Clinical setbacks, slower-than-expected enrollment, or need for recurrent equity raises create dilution and downward re-rating; manufacturing or regulatory delays could keep shares under pressure.
Momentum
73
Value
43
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $18.00 · Bear $6.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-21 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $18.89
Why
Momentum73 · Δ7d -5.9
Value43 · Δ7d +0.1
Sentiment69 · Δ7d +8.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
73
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.9
Δ21d
-4.9
Value
43
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
69
33% active weight
Current posture
7d trendImproving
Δ7d
+8.0
Δ21d
+11.9
Why this grade
Composite grade B. Momentum 72.9 / Value 43.1 / Sentiment 68.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.49B
Beta
1.36
Shares Out
121.56M
P/E (TTM) · Derived
69.7
P/S (TTM)
11.93
P/FCF (TTM) · Derived
-7.36
Rev YoY
-89.7%
EPS YoY
-400.2%
Gross Margin
-
Op Margin
-167.8%
Net Debt
-$636.46M
Current Ratio
7.36
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology